First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

A. Emens, Leisha; Adams, Sylvia; H. Barrios, Carlos; Dièras, Véronique; Iwata, Hiroji; Loi, Sherene; S. Rugo, Hope; Schneeweiß, Andreas; P. Winer, Eric; Patel, Shilpen; Henschel, Volkmar; Swat, A.; Kaul, Manika; Molinero, Luciana; Patel, Shilpen; Chui, S.Y.; Schmid, P.

doi:10.1016/j.annonc.2021.05.355

Public

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

Published in Annals of Oncology • Jul 1, 2021

Authors:

Leisha A. Emens

Sylvia Adams

Carlos H. Barrios

Abstract

BACKGROUND: Guidelines recommend atezolizumab plus nab-paclitaxel (A + nP) for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer expressing programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (IC), based on IMpassion130. We report th...

Subject

Medicine

Atezolizumab

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!